Company Performance - Organogenesis reported a quarterly loss of $0.13 per share, missing the Zacks Consensus Estimate of $0.04, and compared to a loss of $0.02 per share a year ago, representing an earnings surprise of -425% [1] - The company posted revenues of $86.69 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.06%, and down from $109.98 million year-over-year [2] - Over the last four quarters, Organogenesis has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Organogenesis shares have increased approximately 61.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $143.96 million, and for the current fiscal year, it is $0.16 on revenues of $508.6 million [7] Industry Outlook - The Medical - Drugs industry, to which Organogenesis belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Core Viewpoint - Assembly Biosciences reported a quarterly loss of $1.17 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.01, indicating a positive earnings surprise of 41.79% [1] Financial Performance - The company posted revenues of $9.42 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 21.38%, compared to $5.79 million in the same quarter last year [2] - Over the last four quarters, Assembly Biosciences has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Assembly Biosciences shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The company's current Zacks Rank is 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.59 on revenues of $8.19 million, and for the current fiscal year, it is -$6.78 on revenues of $33.7 million [7] - The trend of estimate revisions for Assembly Biosciences is currently favorable, which could influence future stock movements [5][6] Industry Context - The Medical - Generic Drugs industry, to which Assembly Biosciences belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a strong industry performance potential [8]

Core Viewpoint - Collegium Pharmaceutical reported quarterly earnings of $1.49 per share, exceeding the Zacks Consensus Estimate of $1.43 per share, and showing a slight increase from $1.45 per share a year ago, indicating a 4.20% earnings surprise [1][2] Financial Performance - The company achieved revenues of $177.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.08%, and up from $144.92 million in the same quarter last year [2] - Over the last four quarters, Collegium Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Collegium Pharmaceutical shares have declined approximately 5.6% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.61, with projected revenues of $181.28 million, and for the current fiscal year, the EPS estimate is $6.88 on revenues of $741.38 million [7] - The outlook for the Medical - Drugs industry, where Collegium operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Harrow (HROW) reported a quarterly loss of $0.38 per share, significantly missing the Zacks Consensus Estimate of $0.02, representing an earnings surprise of -2,000% [1] - The company's revenues for the quarter were $47.83 million, falling short of the Zacks Consensus Estimate by 19.88%, but showing an increase from $34.59 million year-over-year [2] Financial Performance - Harrow's loss per share increased from $0.28 a year ago to $0.38 this quarter, indicating a decline in financial performance [1] - The company has surpassed consensus EPS estimates two times over the last four quarters, but missed revenue estimates in the latest quarter [2] Stock Performance - Harrow shares have declined approximately 26.7% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current Zacks Rank for Harrow is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $68.63 million, and for the current fiscal year, it is $0.47 on revenues of $286.4 million [7] - The trend of estimate revisions for Harrow is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Summary: BioCryst Pharmaceuticals (BCRX) - BCRX currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] - Over the past week, BCRX shares increased by 6.44%, significantly outperforming the Zacks Medical - Drugs industry, which rose by 0.39% [5] - In a longer timeframe, BCRX's monthly price change is 48.89%, compared to the industry's 6.21% [5] - Over the last quarter, BCRX shares rose by 14.81%, and they have increased by 97.65% over the past year, while the S&P 500 saw movements of -6.34% and 9.94%, respectively [6] - The average 20-day trading volume for BCRX is 5,448,160 shares, indicating strong trading activity [7] Earnings Outlook - In the past two months, 6 earnings estimates for BCRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from -$0.07 to $0.13 [9] - For the next fiscal year, 6 estimates have also moved upwards without any downward revisions [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, BCRX is identified as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.89%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.95, delivering a surprise of -97.92%.Over the last four quarters, the co ...

Company Performance - Stevanato Group reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and up from $0.09 per share a year ago, representing an earnings surprise of 10% [1] - The company posted revenues of $269.93 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.23%, and an increase from $256.24 million year-over-year [2] - Over the last four quarters, Stevanato has topped consensus revenue estimates four times, but has surpassed consensus EPS estimates only once [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - Current consensus EPS estimate for the coming quarter is $0.12 on revenues of $297.06 million, and for the current fiscal year, it is $0.56 on revenues of $1.27 billion [7] - The estimate revisions trend for Stevanato is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Stevanato belongs, is currently in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Stevanato's stock performance [5]

Group 1 - Inotiv, Inc. reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.24, and an improvement from a loss of $0.29 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $124.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.41%, compared to year-ago revenues of $119.04 million [2] - Inotiv shares have declined approximately 57.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] Group 2 - The earnings outlook for Inotiv is uncertain, with current consensus EPS estimates of -$0.14 on revenues of $124.08 million for the upcoming quarter and -$0.83 on revenues of $494.63 million for the current fiscal year [7] - The estimate revisions trend for Inotiv is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which Inotiv belongs, is currently in the top 26% of Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.30%. A quarter ago, it was expected that this specialty drug company would post earnings of $0.52 per share when it actually produced earnings of $0.70, delivering a surprise of 34.62%.Over the last four ...

Core Insights - Amphastar Pharmaceuticals reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.66 per share, but down from $1.04 per share a year ago, indicating a 29% year-over-year decline in earnings [1] - The company posted revenues of $170.53 million for the quarter, missing the Zacks Consensus Estimate by 0.69% and down from $171.84 million a year ago, marking a slight revenue decrease [2] - Amphastar's stock has underperformed, losing approximately 35.7% year-to-date compared to the S&P 500's decline of 4.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.71, with expected revenues of $173.78 million, while the estimate for the current fiscal year is $3.14 on revenues of $738.05 million [7] - The trend of earnings estimate revisions for Amphastar is mixed, leading to a Zacks Rank of 3 (Hold), suggesting the stock is expected to perform in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which Amphastar belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]